Novarel (Chorionic Gonadotropin)
Novarel has a gonadotropic, mainly luteinizing effect. In women, it promotes ovulation, the formation and hormonal activity of the corpus luteum. In men, it stimulates interstitial cells of the gonads, primarily Leydig cells, thereby enhancing the synthesis of testosterone and partially spermatogenesis, activates the development of the genitals and secondary sexual characteristics, while cryptorchidism promotes the lowering of the testicles.
Decrease in the function of the gonads in men and women caused by a violation of the hypothalamus and pituitary gland:
- interstitial-pituitary insufficiency (Simmonds disease, Sheehan’s syndrome, panhypopituitarism of any etiology, adiposogenital dystrophy, pituitary dwarfism with symptoms of sexual infantility, hypogonadymonotropism, hypogonadymonotropism);
- ovaries dysfunctions and related infertility;
- late sexual development;
- threatening miscarriage in the first trimester;
- dysfunctional uterine bleeding in women of childbearing age;
- bilateral cryptorchidism in children;
- unilateral cryptorchidism after surgical treatment with signs of eunuchoidism;
- differential diagnosis of primary and secondary hypogonadism in men.
Dosage and administration
Intramascular application, in doses of 500-3000 units/day.
- Men – 2-3 times a week, the course lasts for 4 weeks with intervals of 4-6 weeks. 3-6 courses should be conducted for 6-12 months; for diagnostic purposes – at 1500-3000 units/day for 5 days.
- Women with anovulatory cycles, starting dosage of Novarel is 10-12 days, 3000 units 2-3 times with an interval of 2-3 days or 1500 units 6-7 times every other day.
- Pituitary dwarfism with the phenomena of sexual infantilism – 500-1000 units 1-2 times a week for 1-2 months with repeated courses.
- Cryptorchidism, children under 10 years old – 500-1000 units, 10-14 years old – 1500 units 2 times a week for 4-6 weeks with repeated courses.
The mos common contraindications of Novarel are:
- pituitary tumors;
- inflammatory genitourinary diseases;
- hormone-active tumors of the sex glands;
- absence of the sex glands (congenital or after surgery);
- early onset of menopause;
- Allergic reactions;
- Enlargement of the testicles located in the inguinal canals, preventing their further omission;
- Premature puberty;
- Genital degeneration;
- Atrophy of the seminiferous tubules (due to inhibition of production FSH as a result of stimulation of the androgens and estrogens’ production);
- A decrease in the sperm volume in the ejaculate (with drug abuse in men).
It is used in combination with menopausal gonadotropin in the treatment of infertility.
In women, ovarian hyperstimulation syndrome may occur with an increase in their size.
Follow precautious measures if you have coronary artery disease, hypertension, renal failure, bronchial asthma, migraine.